Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 18/20 | 0.62 |
| ▸ | JAK1 | P23458 | 8/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30465847 | 1.00 | TYK2 (0.62) | TYK2JAK1CYP2C19JAK2KAT2B | |
| SCHEMBL25670916 | 0.93 | TYK2 (0.53) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL25669827 | 0.91 | TYK2 (0.63) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL25670928 | 0.87 | KAT2B (0.53) | TYK2JAK1CYP2C19JAK2KAT2B | |
| SCHEMBL25670653 | 0.86 | TYK2 (0.52) | TYK2JAK1CYP2C19JAK2KAT2B | |
| SCHEMBL30465841 | 0.86 | TYK2 (0.52) | TYK2JAK1CYP2C19JAK2KAT2B | |
| SCHEMBL26462376 | 0.85 | TYK2 (0.73) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL31017330 | 0.82 | KAT2B (0.55) | TYK2JAK1KAT2BBAZ2BPDE4D | |
| SCHEMBL23941365 | 0.81 | TYK2 (0.68) | TYK2JAK1CYP2C19JAK2 | |
| SCHEMBL30185852 | 0.81 | TYK2 (0.68) | TYK2JAK1CYP2C19JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109120-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023108536-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885CYP2C19 3748/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885CYP2C19 3748/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | TYK2 1/4885JAK1 3/4885CYP2C19 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.